TREATMENTMAP

Serial Number 86266118
602

Registration Progress

Application Filed
Apr 29, 2014
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

TREATMENTMAP

Basic Information

Serial Number
86266118
Filing Date
April 29, 2014
Abandonment Date
October 31, 2018
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
602
Status Date
Nov 30, 2018
Classes
009 042 044

Rights Holder

Molecular Health GmbH

03
Address
Belfortstr. 2
Heidelberg 69115
DE

Ownership History

Molecular Health GmbH

Original Applicant
03
Heidelberg DE

Legal Representation

Attorney
Andrew Baum

USPTO Deadlines

All Deadlines Cleared

All 3 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

48 events
Date Code Type Description Documents
Nov 30, 2018 ABN2 O ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE Loading...
Nov 30, 2018 MAB2 O ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND Loading...
Apr 30, 2018 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Apr 30, 2018 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Apr 30, 2018 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Apr 26, 2018 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Oct 23, 2017 CNSL R SUSPENSION LETTER WRITTEN Loading...
Oct 23, 2017 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Oct 23, 2017 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Oct 12, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 12, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 4, 2017 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Apr 6, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 6, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 6, 2017 CNSL R SUSPENSION LETTER WRITTEN Loading...
Apr 6, 2017 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Apr 6, 2017 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Mar 30, 2017 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Sep 30, 2016 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Sep 30, 2016 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Sep 30, 2016 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Sep 17, 2016 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Mar 16, 2016 CNSL R SUSPENSION LETTER WRITTEN Loading...
Mar 16, 2016 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Mar 16, 2016 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Mar 10, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Mar 10, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Mar 3, 2016 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Oct 6, 2015 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Oct 6, 2015 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Oct 6, 2015 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Sep 30, 2015 RCCK S SUSPENSION CHECKED - TO ATTORNEY FOR ACTION Loading...
Mar 16, 2015 CNSL R SUSPENSION LETTER WRITTEN Loading...
Mar 16, 2015 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Mar 16, 2015 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Feb 23, 2015 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 23, 2015 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 16, 2015 ALIE A ASSIGNED TO LIE Loading...
Feb 12, 2015 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Feb 9, 2015 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 9, 2015 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Aug 13, 2014 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 13, 2014 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 13, 2014 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 11, 2014 DOCK D ASSIGNED TO EXAMINER Loading...
May 14, 2014 MPMK E NOTICE OF PSEUDO MARK E-MAILED Loading...
May 13, 2014 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 2, 2014 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 009
(Based on 44(d) Priority Application) (Based on Intent to Use) Medical and clinical laboratory apparatus and instruments for next generation sequencing of genomic DNA for the purpose of cancer diagnostic molecular testing, in particular, cancer genomic testing and testing of genomic changes, and related automated decision support tools for diagnostic and therapeutic application, namely, computer application software and hardware for use with the laboratory apparatus and instruments
First Use Anywhere: 0
First Use in Commerce: 0
Class 042
(Based on 44(d) Priority Application) (Based on Intent to Use) Data collection for scientific research, analytical and clinical purposes, in particular the collection and systematic sorting of patient's specific molecular, genomic and/or clinical data, in particular relating to genomic changes, in particular relating to cancer genomic changes; providing medical research information through the collection and analysis of genetic information and information regarding the treatment of cancer and other diseases and disorders; scientific clinical studies in the field of medicine; data collection for scientific research and analytical purposes, in particular the collection of mathematical and statistical data, clinical data, patient's genomic data and data of clinical studies relating to patient's clinical responses to drug treatments and treatment regimes; compiling data for research and analytical purposes in the field of medical science and diagnostics, in particular compiling patient specific molecular and genomic data, in particular cancer genomic data; scientific, technical and research services, namely, scientific, technical and medical research for medical purposes in the field of medical diagnostic and optimization of treatment regimes; providing medical and scientific research information and scientific research consulting in the fields of pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis and interpretation of analysis services in the field of next generation sequencing (NGS), namely, the analysis and interpretation of data obtained from cancer patients, specifically patient's genomic changes that contribute to a patient's unique cancer disease; providing an online database featuring medical, pharmaceutical, biological and genomic scientific research information for medical and diagnostic purposes; providing an online searchable database in the fields of medical, pharmaceutical, biological, clinical and genomic scientific research information for scientific research, analytical and clinical purposes; providing an online searchable database featuring scientific research in the fields of cancer medicine, translational medicine, interventional epidemiology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis; design and development of computer software in the fields of biology, medicine, and bioinformatics; design and development of computer software for integration of patient's specific data, molecular test results, clinical studies and scientific results; providing online non-downloadable computer software for use by healthcare professionals for medical diagnostic and treatment, in particular in the field of cancer diagnosis and therapy; design and development of databases featuring biomarker data; providing an online searchable database featuring scientific research information in the fields of analysis and optimization of protocols used in cancer treatment, for medical, diagnostic and clinical use; Software as a Service (SAAS) services featuring software for providing information for patient's treatment by enabling the retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical diagnostic and treatment research purposes; medical research and scientific research and scientific consulting services, in particular designing and conducting scientific research drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others; providing pharmaceutical scientific and medical research information, in particular research information about drug safety and drug compatibility in relation to cancer therapy and the treatment of individual patients; consulting services in the fields of pharmaceuticals and genetics, in particular conducting scientific research in drug safety and dosage assessment and drug compatibility studies in the field of cancer treatment therapy for others; electronic storage of medical data and information for physicians and healthcare professionals; providing an on-line, non-downloadable computer platform for purposes of storing and providing information about patient's individual cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice
First Use Anywhere: 0
First Use in Commerce: 0
Class 044
(Based on 44(d) Priority Application) (Based on Intent to Use) Providing online databases featuring medical information and diagnostic, prophylactic and therapeutic properties of pharmaceuticals, and genomic information as it relates to medical diagnosis and treatment; pharmaceutical consulting services in pharmaceuticals and genetics in relation to patient medical treatment options, in particular in the field of clinical diagnostics and therapy, in particular in the field of cancer diagnostics and cancer therapy; medical consulting services with respect to the treatment and diagnosis of individuals with cancer in the fields of clinical pharmacology and the analysis of dose-effect relationships for treatment purposes; medical consulting services in the fields of patient treatments and treatment protocols for cancer
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Pseudo Mark
TREATMENT MAP

Classification

International Classes
009 042 044